Richard P Boucher

US Patent:

7981898, Jul 19, 2011

Filed:

Sep 7, 2007

Appl. No.:

11/852003

Inventors:

Michael Ross Johnson - Chapel Hill NC, US
Richard C. Boucher - Chapel Hill NC, US
Andrew J. Hirsh - Durham NC, US

Assignee:

Parion Sciences, Inc. - Durham NC

International Classification:

A61K 31/4965

US Classification:

51425506, 51425505

Abstract:

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

US Patent:

8058278, Nov 15, 2011

Filed:

Sep 7, 2007

Appl. No.:

11/851803

Inventors:

Michael Ross Johnson - Chapel Hill NC, US
Richard C. Boucher - Chapel Hill NC, US
Andrew J. Hirsh - Durham NC, US

Assignee:

Parion Sciences, Inc. - Durham NC

International Classification:

A61K 31/4965

US Classification:

51425505, 51425506

Abstract:

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

US Patent:

8163758, Apr 24, 2012

Filed:

Jun 11, 2007

Appl. No.:

12/304006

Inventors:

Michael Ross Johnson - Chapel Hill NC, US
Andrew J. Hirsh - Durham NC, US
Richard C. Boucher - Chapel Hill NC, US
Jianzhong Zhang - Rensselaer NY, US

Assignee:

Parion Sciences, Inc. - Durham NC

International Classification:

A61K 31/4965

US Classification:

51425506, 544407

Abstract:

Provided is class of sodium channel blockers. One example of such a compound is shown by the following formula:.

US Patent:

8288391, Oct 16, 2012

Filed:

Apr 3, 2008

Appl. No.:

12/061864

Inventors:

Michael R. Johnson - Chapel Hill NC, US
Richard C. Boucher - Chapel Hill NC, US
Andrew J. Hirsh - Durham NC, US

Assignee:

Parion Sciences, Inc. - Durham NC

International Classification:

A61K 31/4965

US Classification:

51425506

Abstract:

The present invention relates to blocking salt taste using compounds of Formula I as defined herein.

US Patent:

8551534, Oct 8, 2013

Filed:

Oct 10, 2008

Appl. No.:

12/249175

Inventors:

Richard C. Boucher - Chapel Hill NC, US
Michael Ross Johnson - Chapel Hill NC, US

Assignee:

Parion Sciences, Inc. - Durham NC

International Classification:

A61K 33/00

US Classification:

424661

Abstract:

The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject.

US Patent:

20010034349, Oct 25, 2001

Filed:

Feb 20, 2001

Appl. No.:

09/789256

Inventors:

Richard Boucher - Chapel Hill NC, US

International Classification:

A61K031/4965

US Classification:

514/255060

Abstract:

A method of hydrating nasal airway surfaces in a subject in need of such treatment comprises topically applying a sodium channel blocker to a nasal airway surface of the subject in an amount effective to inhibit the reabsorption of water by the surface. The channel blocker may be a pyrazinoylguanidine sodium channel blocker, such as benzamil, phenamil, amiloride, or a pharmaceutically acceptable salts thereof. The method may further comprise the step of topically applying a P2Yreceptor agonist to a nasal airway surface of the subject in an amount effective to stimulate chloride secretion by the nasal airway surface. In a preferred embodiment, the sodium channel blocker is a covalent conjugate of a pyrazinoylguanidine sodium channel blocker and a non-absorbable carrier moiety (e.g., albumin, polyethylene glycol). Such compounds may also be administered to other mucosal surfaces where it is desired to inhibit the reabsorption of water.

US Patent:

20010041682, Nov 15, 2001

Filed:

May 7, 2001

Appl. No.:

09/850609

Inventors:

Monroe Stutts - Chapel Hill NC, US
Richard Boucher - Chapel Hill NC, US
Eduardo Lazarowski - Durham NC, US
Cara Geary - Seattle WA, US

International Classification:

A61K031/7076
A61K031/7068

US Classification:

514/047000, 514/051000

Abstract:

A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): wherein n is from 1 to 6; X is —OH or —SH; A and B are each independently selected from the group consisting of:  wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.

US Patent:

20020099023, Jul 25, 2002

Filed:

Mar 1, 2002

Appl. No.:

10/087355

Inventors:

Richard Boucher - Chapel Hill NC, US

International Classification:

A61K031/70
A61K031/198
A61K031/19
A61K031/14
A61K033/14
A01N033/12

US Classification:

514/023000, 424/646000, 424/663000, 424/664000, 514/557000, 514/564000, 514/642000

Abstract:

Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.